PetVivo Holdings, Inc. (NASDAQ: PETV), is new to the NASDAQ and has historically been a light trader in terms of volume. September however marked...
Some of the largest healthcare companies in the world include UnitedHealth Group Inc. (NYSE: UNH), Pfizer Inc. (NYSE: PFE), and Abbvie Inc. (NYSE: ABBV). These companies are currently sitting above or close to their all-time-high.
In December, ATWET Technologies, Inc. (OTC Pink: ATWT) announced the finalization of its $1.96 million SafeBus Technologies deal which secured them a strategic =position in the $250 Billion Child Safety Industry.
In other ongoing research looking at cancer vaccines, the Cancer Research Institute, in partnership with the Parker Institute for Cancer Immunotherapy, is studying a combination of a vaccine with the adjuvants Flt3 ligand and poly-ICLC plus the checkpoint inhibitor nivolumab (Opdivo) and standard-of-care radiation in castrate-resistant prostate cancer. Results are expected in the next six to 12 months, said Jill O’Donnell-Tormey, chief executive officer and director of scientific affairs at the Cancer Research Institute.
COMPANY SUMMARY On June 22, 2020, Emerald Organic Products Inc. (OTCPK: EMOR), a Nevada Corporation, changed its name to Healixa Inc., to reflect the company’s...
We may find out whether this is going to be a problem sooner than you’d think. Moderna NASDAQ: MRNA is working with the National Institute of Allergy and Infectious Diseases — which helped it design its original Covid vaccine — to test an updated version of its vaccine that targets the variant first spotted in South Africa, B.1.351. That variant appears to be able to evade immune responses triggered by earlier versions of the virus.
Look at Healixa, Inc. (OTC Pink: EMOR)
Regarding VX-864, its experimental treatment for the rare, inherited lung disease called alpha-1 antitrypsin deficiency, Vertex said a readout of a Phase 2 study is expected in the first half of the year. Last October, Vertex was forced to shelve its first drug for alpha-1 antitrypsin deficiency due to liver toxicity. Independent study monitors are taking regular looks at the safety data from the ongoing VX-864 study, and to date, patient enrollment continues, Vertex said Monday.